Prof. Dr. Lafosse and RevArte Featured in Belgian Media for Integrating neuroClues® in Neurorehabilitation
At RevArte in Edegem, clinicians are exploring how eye movements can reveal neurological disorders years before symptoms …
neuroClues is ISO27001:2022 certified ensuring the security of patient & hospital data
Since April 3rd 2026 neuroClues is certified ISO27001:2022 for Information Security Management Systems by AFNOR. This ce …
Join the Adventure: Become a neuroClues Shareholder
Brussels, 27 January 2026 — Today, we at P3lab (doing business as neuroClues) are launching our crowdfunding campaign on …
Clinical Get Together 2024 – Recap
Clinical Get Together 2024 Welcome to the recap of our recent scientific evening, held in conjunction with the JNLF 2024 …
neuroClues® secures €5 million to launch its groundbreaking technology, set to support the early diagnosis of Parkinson’s disease and other neurological disorders
Paris, April 30, 2024 – neuroClues®, a French-Belgian medtech company specializing in the diagnosis of neurodegenerative …
The eyes: mirrors of how our brain works. A guest opinion in ADN.
An article written by our co-founders Antoine Pouppez and Pierre Pouget, and published on ADN: NeuroClues, a start-up de …
